← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › BACTERIAL VACCINES › Meningococcal vaccines
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
J07AH08
Forms & Strengths
- 0.5 mL solution for injection
- containing 4mcg meningococcus A polysaccharide
- 4mcg meningococcus C polysaccharide
- 4mcg meningococcus W-135 polysaccharide
- 4mcg meningococcus Y polysaccharide
Adult Dosing
- single dose of 0.5 mL
- administer intramuscularly
- booster doses may be required
- repeat doses every 5 years if risk remains
Pediatric Dosing
- 2 months to 10 years: 0.5 mL single dose intramuscularly
- over 10 years: same as adult dosing
- catch-up vaccination for high risk groups
Indications
- active immunization against invasive meningococcal disease
- prevention of meningitis, septicemia, caused by Neisseria meningitidis A,C,Y,W-135
- high risk populations such as travelers, military personnel, college students
Mechanism of Action
- induces immunity by stimulating antibodies against meningococcal antigens
- activates immune response, enhances phagocytosis, killing of bacteria
Contraindications
- severe allergic reaction to previous meningococcal vaccine or components
- known hypersensitivity to diphtheria toxoid, latex
Adverse Reactions
- pain, redness, swelling at injection site
- fatigue, headache, fever, chills, nausea, vomiting
- rare: allergic reactions, anaphylaxis, Guillain-Barre syndrome
Drug Interactions
- may interfere with immune response to other live vaccines
- concurrent administration with other vaccines may enhance immune response
- use caution when co-administering with immunosuppressants
Curated Content: Needs Vetting Before Put to Clinical Use